Forte Biosciences, Inc. (FBRX)

Forte Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	49.63	76.96	22.24	37.13	41.1	42.04
Short-Term Investments	148.83	-	36.12	-	-	-
Cash & Short-Term Investments	198.46	76.96	58.37	37.13	41.1	42.04
Cash Growth	86.97%	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Other Receivables	0.81	0.82	0.13	-	-	-
Receivables	0.81	0.82	0.13	-	-	-
Prepaid Expenses	3.44	2.39	2.65	1.04	0.34	0.39
Other Current Assets	0.39	0.42	0.21	0.17	0.07	0.09
Total Current Assets	203.1	80.59	61.35	38.33	41.51	42.52
Property, Plant & Equipment	0.09	0.13	0.08	0.11	-	-
Long-Term Deferred Charges	-	-	-	-	-	0.11
Other Long-Term Assets	2.55	2.06	0.14	0.54	0.49	0.68
Total Assets	205.74	82.78	61.56	38.98	42	43.31

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	14.01	9.99	4.88	1.42	1.15	0.95
Accrued Expenses	4.94	9.84	4.2	2.24	2.03	0.81
Other Current Liabilities	1.34	0.93	-	-	-	-
Total Current Liabilities	20.29	20.75	9.08	3.67	3.18	1.76
Other Long-Term Liabilities	1.66	1.04	-	-	-	-
Total Liabilities	21.95	21.79	9.08	3.67	3.18	1.76

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.01	0.01	0	0.02	0.02
Additional Paid-In Capital	452.67	284.35	206.46	153.83	125.84	114.7
Retained Earnings	-268.84	-223.37	-154	-118.52	-87.04	-73.17
Comprehensive Income & Other	-0.05	0	0.01	0	-	-
Total Common Equity	183.79	60.99	52.48	35.31	38.82	41.55
Shareholders' Equity	183.79	60.99	52.48	35.31	38.82	41.55
Total Liabilities & Equity	205.74	82.78	61.56	38.98	42	43.31

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash (Debt)	198.46	76.96	58.37	37.13	41.1	42.04
Net Cash Growth	86.97%	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Net Cash Per Share	10.26	5.23	20.02	29.40	59.11	75.25
Filing Date Shares Outstanding	25.19	18.77	6.58	1.46	0.84	0.59
Total Common Shares Outstanding	24.44	17.83	6.39	1.45	0.84	0.59
Working Capital	182.81	59.84	52.27	34.66	38.33	40.76
Book Value Per Share	7.52	3.42	8.21	24.30	46.21	70.40
Tangible Book Value	183.79	60.99	52.48	35.31	38.82	41.55
Tangible Book Value Per Share	7.52	3.42	8.21	24.30	46.21	70.40
Machinery	0.24	0.24	0.13	0.12	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error